Despite considerable controversy surrounding the third interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-I), which indicate a benefit of sentinel lymph node biopsy (SLNB) on disease-free survival in melanoma, the procedure is carried out routinely, according to a report published online in BMJ. Noting that results from the MSLT-I third interim analysis generated considerable controversy, Ingrid Torjesen, a freelance journalist based in London, discusses issues surrounding the use of SLNB in melanoma. Read more here.
Study mentioned: Torjesen I. Sentinel node biopsy for melanoma: unnecessary treatment? BMJ. 2013 Jan 8;346:e8645. PMID: 23299845
No comments:
Post a Comment